Market open
7,443.00
p
Change
+172.00 +2.37%
Volume
Volume 1.43m
Apr 15, 2021, 3:07 p.m.
Quotes are delayed by 20 min
Previous close
7,271.00 p
7,443.00 p
Change
+172.00 +2.37%
Day low
Day high
7,237p
7,449p

52 week low
52 week high
6,736p
10,120p

Market cap
£95.45B
Average volume
2.93M
P/E ratio
39.29
Rev. per Employee
£282,763
EPS
1.89
Dividend
137.40
Div yield
2.78%
Ex dividend date
2/25/21
MarketWatch News on AZN
-
Miners drive up London markets after Goldman puts buy rating on Glencore
- Barbara Kollmeyer
-
Denmark to halt use of AstraZeneca vaccine altogether: reports
- Steve Goldstein
-
European stocks struggle for traction. Shares of LVMH and SAP climb on results.
- Barbara Kollmeyer
- Loading more headlines...
Other News on AZN
-
Roche’s Immunotherapy Drug Extended Patients’ Lives
- The Wall Street Journal Interactive Edition
-
In U.K., Barriers Rising Against Foreign Deals
- The Wall Street Journal Interactive Edition
-
Celgene Profit Surges, Driven by Revlimid Sales
- The Wall Street Journal Interactive Edition
-
AstraZeneca Reports Fall in First-Quarter Profit
- The Wall Street Journal Interactive Edition
-
Billion-Dollar Health Startups
- The Wall Street Journal Interactive Edition
-
Valeant to Buy Salix for About $10 Billion
- The Wall Street Journal Interactive Edition
-
New Cancer Technology Cheers Investors
- The Wall Street Journal Interactive Edition
-
Valeant Nears Deal to Buy Salix
- The Wall Street Journal Interactive Edition
-
Actavis Changing Name to Allergan
- The Wall Street Journal Interactive Edition
-
Pharma Must Launch Itself Back
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
AstraZeneca Deals Up a Tricky 2015
- The Wall Street Journal Interactive Edition
-
Pfizer to Buy Hospira for $16 Billion
- The Wall Street Journal Interactive Edition
-
Astra to Buy Actavis Portfolio
- The Wall Street Journal Interactive Edition
-
New Outsourcing Frontier in India: Monitoring Drug Safety
- The Wall Street Journal Interactive Edition
-
AstraZeneca to Harness Benefits of Genome-Editing Technology
- The Wall Street Journal Interactive Edition
-
Pfizer Sales Hit by Stronger Dollar
- The Wall Street Journal Interactive Edition
-
Teva: FDA Approves Generic Version of AstraZeneca Heartburn Drug
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Pharma Grows Itself a New Challenge -- Overheard
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on AZN
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com